Want to see AU:RHY full AI Analyst Report?
Rhythm Biosciences Ltd. (RHY) AI Stock Analysis
Top Page
Rhythm Biosciences Ltd.
(ASX:RHY)
Weak financial performance due to ongoing losses and cash burn is the dominant factor, further pressured by unfavorable technical analysis with the stock in a downtrend.
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 22.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 216.53K
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 0.95
- Revenue Growth
- 239.64%
- EPS Growth
- -37.21%
- Country
- Australia
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Company Description
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduc...
How the Company Makes Money
null
Rhythm Biosciences Ltd. Financial Statement Overview
Summary
Revenue volatility with sharp contractions, sustained net losses, and negative margins highlight significant challenges in scaling and profitability.
Income Statement
23NegativeBalance Sheet
41NeutralCash Flow
18Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.34K | 85.34K | 3.19M | 1.69M | 3.10M | 2.43M |
| Gross Profit | -4.40M | -4.40M | 2.97M | -1.36M | 2.91M | -101.48K |
| EBITDA | -7.27M | -7.27M | -3.53M | -8.35M | -11.11M | -11.10M |
| Net Income | -5.93M | -5.93M | -3.83M | -6.86M | -8.22M | -8.79M |
Balance Sheet | ||||||
| Total Assets | 4.78M | 4.78M | 2.83M | 1.52M | 7.70M | 8.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.44M | 3.44M | 1.48M | 754.50K | 4.17M | 7.60M |
| Total Debt | 247.98K | 247.98K | 1.11M | 163.82K | 84.61K | 170.14K |
| Total Liabilities | 1.14M | 1.14M | 2.17M | 651.54K | 1.82M | 1.07M |
| Stockholders Equity | 3.64M | 3.64M | 659.89K | 867.17K | 5.87M | 7.37M |
Cash Flow | ||||||
| Free Cash Flow | -5.26M | -5.26M | -2.94M | -6.22M | -7.06M | -6.24M |
| Operating Cash Flow | -5.23M | -5.23M | -2.92M | -6.14M | -6.96M | -6.21M |
| Investing Cash Flow | -22.75K | -22.75K | -582.96K | -82.28K | -99.12K | -27.01K |
| Financing Cash Flow | 7.22M | 7.22M | 4.19M | 2.80M | 3.63M | 11.85M |
Rhythm Biosciences Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHY, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 24.49 is Positive, neither overbought nor oversold. The STOCH value of -17.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RHY.
Rhythm Biosciences Ltd. Peers Comparison
Overall Rating
AU:BDX43Neutral
AU:LDX41Neutral- AU:RHY40Underperform
AU:GSS39Underperform
AU:MAP38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:BDX | 43Neutral | AUD 30.97M | -4.18 | -881.94% | ― | 743.51% | -1.52% |
| AU:LDX | 41Neutral | AUD 59.29M | -6.49 | -35.89% | ― | 1.36% | 39.13% |
| AU:RHY | 40Underperform | AUD 22.94M | -3.56 | -205.17% | ― | 239.64% | -37.21% |
| AU:GSS | 39Underperform | AUD 17.72M | -1.27 | -35.10% | ― | -9.10% | 31.75% |
| AU:MAP | 38Underperform | AUD 25.62M | -1.00 | -75.96% | ― | -5.81% | -3.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:RHY | Rhythm Biosciences Ltd. | 0.06 | -0.03 | -29.21% | |
| AU:BDX | BCAL Diagnostics Limited | 0.08 | -0.01 | -6.67% | |
| AU:LDX | Lumos Diagnostics Holdings Ltd. | 0.06 | -0.18 | -75.00% | |
| AU:GSS | Genetic Signatures Ltd. | 0.08 | -0.22 | -73.56% | |
| AU:MAP | Microba Life Sciences Limited | 0.03 | -0.04 | -56.41% |
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences Study Flags Major Cost Savings from ColoSTAT in Public Hospitals
Rhythm Biosciences has reported results from an independent health economic study indicating that ColoSTAT, when used by GPs to triage patients with bowel symptoms, could substantially reduce colonoscopy demand in Australian public hospitals. The mod...
Rhythm Biosciences Files Updated Corporate Governance Statement With ASX
Rhythm Biosciences Ltd., an Australian biotechnology company, operates under the ASX listing framework with a focus on transparent corporate governance and investor disclosure. Its governance practices cover board responsibilities, executive oversigh...
Rhythm Biosciences Sets Date for 2026 AGM and Director Nomination Deadline
Rhythm Biosciences has scheduled its 2026 Annual General Meeting for 24 November in Melbourne, in line with ASX listing requirements. The company has also set 6 October 2026 as the deadline for written nominations from individuals seeking election to...
Rhythm Biosciences Names Interim Chair as Board Reshuffles During Commercialisation Push
Rhythm Biosciences has announced that Chair and Non-Executive Director Gavin Fox-Smith has resigned from the board with immediate effect, citing an inability to commit the time required as the company advances its commercialisation strategy. The boar...
Rhythm Biosciences Advances ColoSTAT NHS Assessment With Key Technology Transfer Milestone
Rhythm Biosciences has announced that the Southern Hub research team at the Royal Surrey NHS Foundation Trust in England has successfully completed technology transfer for its ColoSTAT blood test for bowel cancer. The Hub can now run the ColoSTAT ass...
Rhythm Biosciences Adds Independent Director Maureen Baker to Board
Rhythm Biosciences Limited has announced the appointment of Maureen Baker as a director effective 27 August 2026, expanding the company’s board. According to the initial director’s interest notice lodged with the ASX, Baker holds no direc...
Rhythm Biosciences Widens Annual Loss but Strengthens Asset Backing
Rhythm Biosciences reported a significantly wider loss for the year ended 30 June 2026, with after-tax loss rising 55% to $5.93 million as other income from ordinary activities fell 48% to $1.74 million. The company did not declare any dividends, but...
Rhythm Biosciences strengthens board to support global cancer diagnostics push
Rhythm Biosciences Ltd, a Melbourne-based cancer diagnostics company, develops blood tests such as ColoSTAT for early colorectal cancer detection and uses the geneType platform to provide multi-disease genetic risk assessments. Its solutions target i...
Rhythm Biosciences Options Lapse Trims Potential Share Pool
Rhythm Biosciences has reported the expiry of 375,000 unexercised options with an exercise price of $0.20 that were due to expire on 20 August 2026. The lapse of these options marginally reduces the company’s pool of potential future shares, si...
Rhythm Biosciences Positions Itself as ASX Life Sciences Growth Play
Rhythm Biosciences has released a presentation targeted at investors and stakeholders, outlining its position as a growth-focused life sciences company on the ASX. The document emphasises that the information is general in nature, subject to ongoing...
Rhythm Biosciences Builds Momentum in ColoSTAT Rollout and Global Partnerships
Rhythm Biosciences reported solid progress in the June quarter, underpinned by a strengthened balance sheet after underwriting about $5.2 million of options to fund ongoing commercial execution. The company is accelerating the rollout of its ColoSTAT...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026